To evaluate the clinical efficacy of Xuefu Zhuyu Formula in the adjuvant treatment of lung cancer and the improvement of coagulation function.Methods:Pubmed，Embase，Cochrane Library，CBM，CNKI，Wanfang and VIP databases were searched from the establishment of each database to March 2020.Literature quality was evaluated using the risk bias assessment tool in the Cochrane Review Manual and included in the meta-analysis.Results:A total of 15 randomized controlled trials were included.Meta-analysis showed clinical efficacy(OR=2.113，95%CI(1.627,2.745，P<0.05)，indicating that Xuefu Zhuyu Formula had certain advantages in the adjuvant treatment of lung cancer patients，and subgroup analysis was conducted for its and pathological types，and for different adjustability interventions.Quality of life(MD=7.05，95%CI(6.06,8.04，P<0.05); the curative effect of TCM syndromes(OR=4.817，95%CI(3.010，7.710，P<0.05) indicated that Xuefu Zhuyu Formula could improve the quality of life and TCM syndromes of patients.Both coagulation function and hemorheology index I2 were>50%，indicating strong heterogeneity.Sensitivity analysis was conducted respectively，and after removing single studies one by one，fixed effect combined with effect size was applied，indicating that all outcome indexes were improved to varying degrees，except for APTT，where P=0.41>0.05，indicating no statistical significance.Conclusion:Xuefu Zhuyu Formula has certain clinical efficacy in the adjuvant treatment of lung cancer，which can improve the quality of life of patients and alleviate their blood stasis syndrome.For patients with hypercoagulable lung cancer，it can improve the abnormal coagulation indicators(PLT，FIB，D-Dimer，APTT，PT)，and reduce the whole blood viscosity and plasma viscosity of patients.Considering the low quality of the included literature，this conclusion still needs to be verified by a large number of high-quality randomized controlled clinical trials.